Skip to main content
. 2020 May 11;4(9):2044–2048. doi: 10.1182/bloodadvances.2020001628

Table 2.

Description of ATL cases

Case Age at ATL diagnosis, y Time in cohort, y Place of birth Ethnic group HIV serology Observed HTLV-1 seroconversion ATL subtype Status (April 2018) Survival time
1 26 5.6 Surinam NM Negative No Lymphoma Dead 0 d
2 45 7.3 French Guiana NM Negative No Lymphoma Unknown Unknown
3 47 8.6 Surinam NM Negative No Lymphoma Alive >10 y
4 29 14.7 Surinam NM Negative No Acute Dead 3.5 mo
5 54 15.7 Surinam NM Negative No Acute Dead 4.6 mo
6 51 18.6 Surinam NM Negative No ND Dead 6.6 mo
7 52 19.9 Surinam NM Negative No Acute Dead 3.9 mo
8 39 21.4 Surinam ND Negative No Lymphoma Dead 1.0 mo
9 59 25.8 Surinam NM Negative No Acute Dead 0.1 mo

ND, not determined; NM, Noir Marron.